Two-Session CME/CPE Webinar Series
Register for each session below to gain access to both webinars.
10:00 am – 1:00 pm ET
Topics
- Hot Topics: Tackling Disparities in IBD Care
- Strategies for Tailoring UC Therapy to the Patient
- Therapeutic Drug Monitoring: Deriving the Greatest Benefit From Treatment
- UC Management in the Era of COVID-19
- On the Horizon: Investigational Agents for UC
- Use of Patient-reported Outcomes to Improve IBD Care
- Shared Decision-making in IBD Care: Patient Perspectives Matter
- Case Studies
- LIVE Question & Answer
10:00 am – 1:00 pm ET
Topics
- Getting the Most From CD Therapies
- Benefits of Therapeutic Drug Monitoring to Individualize Treatment
- Navigating CD Care During the COVID-19 Pandemic
- Looking Toward the Future: Potential Newer Agents for CD
- Navigating the Quagmire of Prior Authorization
- Patient Advocacy
- Case Studies
- LIVE Question & Answer
Series Overview
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), affects an estimated 3 million adults in the United States—and incidence and prevalence is increasing. The virtual IBD Forum 2021 is a 2-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with IBD. Session 1, Ulcerative Colitis and IBD Care: Keys to Optimizing Treatment and Outcomes, will incorporate live didactic presentations and case discussions, covering considerations for pharmacotherapy in patients with UC, TDM, management in the era of COVID-19, shared decision-making, as well as a live question-and-answer session. Session 2, Choosing Wisely: Best Practices in the Management of Crohn’s Disease and Patient-focused IBD Care, will incorporate live didactic presentations and case discussions, covering considerations for pharmacotherapy in patients with CD, management in the era of COVID-19, as well as navigating prior authorizations. It will also highlight connecting with the patient to improve outcomes and includes a live question-and-answer session.
Target Audience
The intended audience for these activities is gastroenterologists, pharmacists, and other health care professionals involved in the management of patients with IBD.
Series Learning Objectives
Upon successful completion of these activities, participants should be better able to:
- Incorporate the latest American College of Gastroenterology guidelines in daily practice.
- Apply appropriate criteria for determining the severity of UC.
- Initiate pharmacotherapy for UC based on optimal positioning of available agents.
- Utilize therapeutic drug monitoring as needed to achieve the best possible outcomes for patients with UC.
- Implement strategies for appropriate care of UC patients during the COVID-19 pandemic.
- Establish the severity of CD to inform treatment decisions.
- Implement optimal positioning of CD therapies in treatment plans.
- Use therapeutic drug monitoring to maximize benefits to patients.
- Initiate steps to ensure appropriate management of CD patients during the COVID-19 pandemic.
- Gain awareness of racial/ethnic and socioeconomic disparities in IBD care.
- Incorporate shared decision-making into clinical practice.
- Consider patient-reported outcomes when making treatment decisions.
- Use therapeutic drug monitoring to maximize benefits to patients with CD.